TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients and enhancing research accuracy.
Research shows 60% of missense mutations destabilize proteins, linking protein folding to genetic diseases, including cataracts and neurological disorders.
A new electrically active transplantable material that can help to regrow cells in the brain and spinal cord could redefine the recovery prospects of patients
A new analysis of U.S. mortality data reveals the disproportionate impact of traumatic brain injuries (TBI) on older adults, males and certain racial and ethnic
This study reveals strong links between calcium intake and reduced colorectal cancer risk, highlighting dietary factors influencing cancer incidence in women.
When Bristol Myers Squibb bought the heart disease-focused biotech MyoKardia for $13 billion in cash in the fall of 2020, it was seen as an
The Johns Hopkins Bloomberg School of Public Health will host an expert briefing for the media to discuss trends in tobacco use, the implications of
A2 Bio has two ongoing Phase I/II clinical trials investigating two of its CAR-T programmes. Credit: THOMAS COEX via Getty Images. US-based biotech company A2
Preparing cancer patients for difficult decisions is an oncologist’s job. They don’t always remember to do it, however.
Light Horse pursues a function-first approach with its genetic editing-based platform. Image credit: Shutterstock/ Hyejin Kang. Light Horse Therapeutics has galloped on to the biotech